ホーム › トリプルネガティブ乳がん › ペンシルベニア
ペンシルベニアにおけるトリプルネガティブ乳がんの臨床試験
ペンシルベニア内の拠点で、トリプルネガティブ乳がんに関する23件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
被験者募集中
30歳以上 · 女性 · 2026/09/25更新 · NCT02945579Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
- Cancer Care Associates Of York ( Site 9517), York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- UPMC, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Lancaster General Health, Lancaster
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- UPMC Magee-Womens Hospital, Pittsburgh
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT03606967A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Lehigh Valley Health Network, Allentown
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
- Local Institution - 0360, Pittsburgh
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Pennsylvania (U Penn), Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/04更新 · NCT04434040ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
- UPMC Hillman Cancer, Pittsburgh
被験者募集中観察研究
18歳以上 · 女性 · 2026/05/01更新 · NCT07332975Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/29更新 · NCT04468061Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Lehigh Valley Health Network, Allentown
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/27更新 · NCT03808337Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
- Thomas Jefferson University Hospital, Philadelphia
被験者募集中
40歳以上 · 全性別 · 2026/01/23更新 · NCT04959474Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- University of Pittsburgh Medical Center, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/29更新 · NCT06249048Role of the Immune Environment in Response to Therapy in Breast Cancer
- Abramson Cancer Center, Philadelphia
被験者募集中観察研究
18歳以上 · 女性 · 2025/07/08更新 · NCT05396612CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Cancer Care Associates of York, York
被験者募集中観察研究
18歳以上 · 女性 · 2025/01/07更新 · NCT06230185ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。